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Autoreactive marginal zone B cells
are spontaneously activated but lymph
node B cells require T cell help
Laura Mandik-Nayak, Jennifer Racz, Barry P. Sleckman, and Paul M. Allen

The Journal of Experimental Medicine

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110

In K/BxN mice, arthritis is induced by autoantibodies against glucose-6-phosphateisomerase (GPI). To investigate B cell tolerance to GPI in nonautoimmune mice, we increased
the GPI-reactive B cell frequency using a low affinity anti-GPI H chain transgene.
Surprisingly, anti-GPI B cells were not tolerant to this ubiquitously expressed and circulating autoantigen. Instead, they were found in two functionally distinct compartments:
an activated population in the splenic marginal zone (MZ) and an antigenically ignorant
one in the recirculating follicular/lymph node (LN) pool. This difference in activation was
due to increased autoantigen availability in the MZ. Importantly, the LN anti-GPI B cells
remained functionally competent and could be induced to secrete autoantibodies in
response to cognate T cell help in vitro and in vivo. Therefore, our study of low affinity
autoreactive B cells reveals two distinct but potentially concurrent mechanisms for their
activation, of which one is T cell dependent and the other is T cell independent.
CORRESPONDENCE
Paul M. Allen:
pallen@wustl.edu
Abbreviations used: Ag, antigen;
ASC, antibody-secreting cell;
Cr, complement receptor;
HELμMT, hen egg lysozyme
Ig tg mice on an IgM-deficient
background; GPI, glucose6-phosphate-isomerase; MZ,
marginal zone; tg, transgenic;
tg neg, transgene negative.

In the B cell compartment, tolerance to many
self proteins is actively maintained by either
purging self-reactive B cells from the repertoire
through clonal deletion and receptor editing or
by functionally silencing them through the induction of anergy (1–5). However, these processes are clearly incomplete, as B cell–driven
autoimmune responses still occur. A prime example is the K/BxN mouse model of rheumatoid arthritis in which mice spontaneously
develop a T and B cell–dependent inflammatory joint disease by 4–5 wk of age (6).
Autoantibodies are key mediators in arthritis
induction and by themselves can transfer disease to most naive strains of mice (7). In this
model, the autoantigen for both the KRN
transgenic (tg) T cells and non-tg B cells has
been identified as the glycolytic enzyme glucose-6-phosphate-isomerase (GPI) (8). It remains unclear how autoreactive B and T cells
escape tolerance induction to this ubiquitously
expressed autoantigen and initiate the pathogenic autoantibody response.
It is difficult to study the mechanisms of
tolerance induction for autoreactive B cells in
unmanipulated animals because of their low
precursor frequency. The use of Ig tg models
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has been invaluable to increase the frequency of
autoreactive B cells, allowing their fate to be
tracked in both healthy and autoimmune mice.
Initial studies used high affinity somatically mutated Ig transgenes directed toward model or
disease-associated antigens (Ags) and defined
several fates for autoreactive B cells in nonautoimmune mice, including clonal deletion, anergy, and receptor editing (1–5, 9–13). These
models were extremely useful and identified the
mechanisms used to induce tolerance in B cells
with high affinity Igs. However, most B cells
undergoing tolerance induction in the BM are
not somatically mutated, and those that are
able to escape tolerance induction most likely
express Igs with low affinity for autoantigens
(14–16). Studies using 10–1,000-fold lower affinity Ig B cell receptor transgenes demonstrate
either only partial tolerance or antigenic ignorance in the autoreactive B cell compartment
(17–19). Collectively, these studies demonstrate
that B cells with low affinity Igs may be able to
escape tolerance mechanisms normally induced
in B cells with high affinity Igs. It is from these
low affinity B cell populations that the autoimmune response is likely to initiate.
Mature peripheral B cells can bedivided into
two main subsets based on surface phenotype:
recirculating follicular B cells (B220+CD1dlowCD21/35intCD23int) and marginal zone (MZ)
1985

B cells (B220+CD1dhighCD21/35highCD23low) (20). These
populations are also physically segregated into different compartments. Follicular B cells are found in both the spleen and
LN, whereas MZ B cells are localized exclusively to the
spleen where they are separated from the B cell follicle by the
marginal sinus (21). MZ B cells are a rare nonrecirculating
B cell population that has been shown to be easily activated
by low levels of antigen (Ag), to be potent APCs for naive
T cells, and has been implicated in autoreactive B cell responses (22, 23). Engagement by self-Ag drives the selection
of B cells into the MZ compartment; however, it remains
controversial whether this is dependent on high or low affinity interactions (21, 22, 24, 25).
To understand how GPI-reactive B cells escape tolerance
induction to the ubiquitously expressed autoantigen GPI,
it was important at the outset to establish how their tolerance
was induced/maintained in nonarthritic mice. To increase
the frequency of GPI-reactive B cells and follow their fate in
nonautoimmune mice, we generated low affinity anti-GPI
Ig tg mice, termed VH147 tg mice. VH147 tg mice are H
chain alone tg mice in which GPI-reactive B cells are identifiable by their ability to bind GPI in a flow cytometry–based
assay, allowing for the simultaneous detection of multiple
VH147 H chain/endogenous L chain pairs. Therefore, these
mice offer the unique opportunity to follow the fate of an
oligoclonal repertoire of low affinity GPI-reactive B cells in
the context of a diverse nonautoimmune B cell repertoire.
In this study, we demonstrate that low affinity GPI-binding
B cells populated both the spleen and the LN of nonautoimmune mice but were dramatically enriched in the MZ of the
spleen. Surprisingly, although the anti-GPI B cells showed
evidence of autoantigen encounter beginning in the BM,
no imprint of tolerance was evident and the GPI-reactive
B cells remained functionally competent to proliferate and
secrete Ig. Importantly, only the anti-GPI B cells found in
the expanded MZ population up-regulated activation markers and spontaneously differentiated into autoantibodysecreting cells in vivo. Although the follicular/LN anti-GPI
B cells were ignorant to self-Ag in nonautoimmune mice,
they were recruited into the autoimmune response by GPIspecific T cell help in vivo. Collectively, these data demonstrate that low affinity self-reactive B cells can participate in
autoantibody responses in both T cell–dependent and –independent mechanisms.
RESULTS
Generation and characterization of KRN5-147
hybridoma and VH147 tg mice
We wished to examine how B cell tolerance to GPI was induced in nonautoimmune mice in a physiologically relevant
context. Ig tg mice using only a H chain transgene have been
used in past studies to increase the frequency of Ag-specific
B cells while retaining a diverse B cell repertoire (12, 13, 22).
In this study, we generated H chain alone tg mice with the aim
of allowing the tg H chain to pair with endogenous L chains
in the mouse to form both GPI- and non-GPI–binding
1986

B cells, thus maintaining a polyclonal B cell repertoire.
To create a low affinity anti-GPI Ig tg mouse, candidate
GPI-binding Igs were identified in hybridoma panels generated from K/BxN mice at the initiation of arthritis. The goal
was to isolate spontaneously arising anti-GPI Igs that were
present in the early phase of arthritis, thus hypothesizing that
these would be from B cells responsible for the induction of
the autoimmune response.
One hybridoma, KRN5-147 (anti-GPI IgG1), was selected based on its ability to bind an epitope on GPI that was
prevalent in arthritic K/BxN serum (unpublished data). In addition, it had a relatively low affinity for GPI (KD2 × 10−6)
by surface plasmon resonance and had an unmutated H chain
V region (unpublished data). These features closely mimic
the Igs of B cells that undergo selection in the BM and possibly escape tolerance induction to join the peripheral B cell
pool (14). To generate the tg construct, the rearranged genomic VDJ fragment of the 147 hybridoma was amplified
by PCR and cloned into an IgM H chain expression vector
(1). Using flow cytometry and allotype-specific antibodies,
the tg Ig protein was expressed and allelically excluded rearrangement of endogenous Ig (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20060701/DC1).
The majority of anti-GPI B cells display an activated
MZ phenotype in the spleen
VH147 tg mice were examined for the presence of anti-GPI
B cells and were found to contain a readily detectable population of GPI binders (Fig. 1 A). As one control, hen egg
lysozyme Ig tg mice on an IgM-deficient background
(HELμMT) were used as a population of non–GPI-binding
B cells to define the GPI+ gate. VH147 tg mice contained
populations of both anti-GPI and non-GPI B cells in the BM,
spleen, LN, and peritoneal cavity with anti-GPI frequencies
ranging from 6–13% of the total B cell population (Fig. 1 A
and not depicted). This demonstrated that the VH147 transgene significantly increased the frequency of GPI-binding B
cells compared with transgene negative (tg neg) mice (0.6–
0.8% GPI+), allowing their fate to be followed in nonarthritic
C57BL/6 mice. Analysis of total B cell numbers in VH147 tg
mice revealed a decrease in the absolute number of B cells
compared with tg neg littermates (6.8 ± 2.4 × 106 vs. 18.4 ±
6.2 × 106; n = 12). This reduction in B cell numbers was not
caused by a transgene integration artifact because a second independently derived founder line showed a similar decrease in
B cell numbers (7.2 ± 4.7 × 106; n = 5). Decreased B cell
numbers have also been noted in other H chain Ig tg mice
and could be caused by deletion of some GPI-binding B cells
in the BM and/or inefficient pairing of the 147 H chain with
many endogenous L chains (9, 10).
To characterize the anti-GPI B cell population in VH147
tg mice, spleen and LN cells were stained with anti-B220,
GPI-his protein, and a panel of cell surface markers used to
define B cell subsets. Anti-GPI B cells in both the spleen and
LN were found in the mature follicular compartment,
B220highCD22highCD1dlowCD21/35intCD23int (Fig. 1 B).
SITE-SPECIFIC ACTIVATION OF AUTOREACTIVE B CELLS | Mandik-Nayak et al.

ARTICLE

Figure 1. Anti-GPI B cells in the spleen exhibit an activated MZ
phenotype, whereas those in the LN are naive mature follicular cells.
Spleen or LN cells from VH147 tg or tg neg B6.K mice were stained with
anti-B220, GPI-his, and antibodies against phenotypic markers or activation
markers and analyzed by flow cytometry. (A) The percentages of GPI-binding
B cells out of total B220+ cells in the spleen are given for the boxed regions.
The GPI+ gate was drawn based on the HELμMT, which contains a monoclonal population of non-GPI-binding B cells. (B) Histograms show surface

marker expression for splenic or LN B220+GPI+ cells from VH147 tg mice
(open histograms) overlaid tg neg B cells (shaded histograms). (C) Histograms show activation marker expression for B220+GPI+ MZ (CD21/35high),
FO (CD21/35int), or LN VH147 tg (open histograms) overlaid unfractionated
tg neg B cells (shaded histograms). (D) Histograms are gated on
B220+CD21/35high MZ B cells from the VH147 tg GPI+ (open histograms)
overlaid GPI− (shaded histograms) populations. n = 5 mice of
each genotype.

Intriguingly, the majority (59.5 ± 8.3%) of GPI-binding
B cells in the VH147 tg spleen were not mature follicular
B cells, but instead had the phenotype of MZ B cells,
CD1dhighCD21/35highCD23low (Fig. 1 B). Consistent with an
increase in MZ B cells, immunofluorescent staining of spleen
sections revealed an expanded MZ in VH147 tg mice; however, we were unable to specifically identify the GPI-binding
B cells in the tissue sections because of their low affinity for
GPI (Fig. S2, available at http://www.jem.org/cgi/content/

full/jem.20060701/DC1; and not depicted). Preferential MZ
B cell development has been reported previously in mice
with reduced B cell numbers (20, 26, 27). Because VH147 tg
mice had a 3–4-fold reduction in B cell numbers, it was
important to distinguish whether the enrichment of GPIbinding B cells in the MZ was simply caused by lymphopenia.
To address this, mixed BM chimeras (VH147 tg + tg neg)
with a more complete B cell compartment (13.9 ± 4.8 ×
106 B cells; n = 4) were generated. The GPI-binding B cells
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were still enriched in the MZ compartment of the mixed
BM chimeric mice (29.4 ± 2.3%) compared with tg neg
chimeric mice (4.1 ± 0.9%), but not to the same extent
as in nonchimeric VH147 tg mice. FACS analysis of nonGPI binders in both the VH147 spleen and LN, with the exception of an elevated level of CD23, closely matched tg neg
B cells, demonstrating that the skewed MZ phenotype was
specific to the GPI-binding B cells (Fig. S3, available at
http://www.jem.org/cgi/content/full/jem.20060701/DC1).
This indicated that reduced B cell numbers may explain part
of the MZ enrichment, but as suggested by others, selfreactivity is likely to have also played a role in their phenotypic skewing (21, 22, 24, 25).
To determine if the GPI-binding B cells in VH147 tg
mice showed evidence of having encountered GPI Ag, the
VH147 CD21/35high MZ and CD21/35int follicular splenic
subsets, as well as LN cells, were stained for activation markers and compared with naive tg neg B cells (Fig. 1 C). Interestingly, only the anti-GPI B cells in the MZ and not the
follicle or LN of VH147 tg mice were activated, expressing
elevated levels of CD44, CD69, CD80, and CD86 and an
increase in cell size (Fig. 1 C). However, they had not formed

germinal centers, as there was no evidence of an expanded
germinal center B cell population in VH147 tg mice by immunofluorescence microscopy or flow cytometry (not depicted). MZ B cells have been reported to be a partially
activated population of B cells, possibly as a result of positive
selection by autoantigen (22). In VH147 tg mice, the GPIbinding MZ B cells expressed even higher levels of the activation markers CD44, CD69, CD80, and CD86 (1.5–3-fold
elevated) compared with non-GPI binding VH147 or tg neg
MZ B cells (Fig. 1 D and not depicted), indicating that their
activation status was not simply a result of their MZ phenotype. Control non-GPI binders in both the spleen and LN
did not express elevated levels of any of the activation markers tested (Fig. S3). Together, these data demonstrate that the
majority of anti-GPI B cells in the spleen were activated MZ
B cells, whereas a minority in the spleen and those in the LN
remained naive mature follicular B cells.

Figure 2. MZ B cells exhibit the highest exposure to GPI autoantigen in vivo. (A) Cells from VH147 tg mice or HELμMT were stained with
a pool of anti-GPI antibodies to determine the percentage of cells bound
to endogenous GPI (top) or exogenous GPI followed by the pool of antiGPI mAbs to determine the total percentage of possible GPI-binders
(bottom). The plots are gated on CD21/35+ cells for the HELμMT spleen,
the VH147 blood and LN, IgM+ cells for the BM, CD21/35int cells for the
follicle, and CD21/35high cells for the MZ. The percentages are given for
the boxed regions. The positive gate is drawn based on the control
HELμMT spleen sample. (B) The percentage of anti-GPI B cells bound to
endogenous GPI was determined by dividing the percentage of cells

staining with anti-GPI antibodies alone by the total percentage of possible GPI binders. Each symbol represents an individual mouse for a total
of n = 5 mice for each organ. The mean percentage of GPI-binding
B cells is represented as a histogram. There is a significantly higher percentage of B cells bound to GPI in the MZ compared with the other organs
(P < 0.0004) and a lower percentage bound in the BM (P < 0.025). The
difference between the BM and peripheral blood is not statistically significant (P = 0.0687). BL, peripheral blood; FO, follicular. (C) The percentage of anti-GPI B cells bound to endogenous GPI in VH147 tg Cr2−/−
mice. There is a significantly higher percentage of B cells bound to GPI in
the MZ (P = 0.001; n = 3 mice).
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MZ B cells exhibit the highest GPI autoantigen
exposure in vivo
The differences in activation phenotype suggested that the
GPI-reactive B cells in the splenic MZ, follicle, and LN have
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had different exposure to autoantigen. To address which population exhibited the highest exposure to GPI and where
GPI-reactive B cells first encountered their autoantigen,
bound GPI was quantitated on anti-GPI B cells isolated from
the BM, peripheral blood, LN, and spleen, separating MZ
and follicular B cells, using flow cytometry (Fig. 2, A and B).
Not all B cells in VH147 tg mice are GPI-reactive; therefore,
for this quantitation, we divided the percentage of cells bound
to endogenous GPI by the percentage of total possible GPI
binders. Endogenous GPI was bound to a percentage of antiGPI B cells in all organs tested. This indicated that anti-GPI
B cells were first exposed to their autoantigen in the BM and
continued to encounter it in the peripheral blood, spleen,
and LN. Consistent with their activated phenotype, the highest percentage of GPI-bound B cells was found in the MZ,
where 43.4 ± 4.8% of the total possible GPI-binding B cells
were bound to GPI (Fig. 2 B). Because MZ B cells have high
levels of the complement receptors (Crs) CD21/35 on their
surface, the GPI could be bound directly to the Ig receptor as
well as indirectly in the form of immune complexes (20). To
test whether the increased endogenous GPI detected on the
MZ B cells was caused by their elevated level of CD21/35,
we bred the VH147 transgene onto a Cr-deficient (Cr2−/−)
background (28). In the absence of Crs, the MZ pool still
contained the highest percentage of B cells bound to endogenous GPI (Fig. 2 C). The percentage of GPI-bound B cells
was actually higher in the MZ of Cr2−/− mice (70.1 ± 6.1%),
perhaps because of the lack of other Cr-expressing cells in the
MZ binding to GPI/anti-GPI immune complexes, leaving
them free to bind the anti-GPI B cells via their Ig receptors.
The VH147 transgene is a H chain alone transgene.
Therefore, it was possible that the activation differences we
observed were the result of differential endogenous L chain
usage by the anti-GPI B cells rather than increased Ag availability. To determine the L chains that generate GPI-binding
Igs when paired with the VH147 H chain, L chains were
cloned from anti-GPI B cells sorted from the spleen or LN.
The majority of GPI binders in both the spleen (52%) and
LN (84%) used the Vκ14-111 L chain (Fig. 3 A), the L chain
used by the original KRN5-147 hybridoma. Sequences using
other Vκ genes were also isolated, indicating that the VH147
H chain could pair with several different L chains to generate
an anti-GPI specificity (Fig. 3 A). Overall, the spleen and LN
GPI-binding populations used a similar set of endogenous
L chains; however, two Vκ sequences (Vκ9-124 and Vκ452) were isolated only from the spleen and one Vκ sequence
(Vκ17-121) only from the LN GPI-binders. To determine if
there was any difference in the relative affinity of these
VH147/Vκ pairs compared with those found in both the
spleen and LN populations, we isolated hybridomas using
these L chains from unmanipulated VH147 tg mice. There
was no clear distinction in the relative GPI affinity between
the L chains found exclusively in the spleen and those found
in both the spleen and LN (Fig. 3 B). Therefore, the spleen
and LN GPI-binding B cells used similar endogenous L chain
repertoires with the same relative affinity for GPI.
JEM VOL. 203, August 7, 2006

To show definitively that MZ anti-GPI B cells were exposed to more autoantigen in vivo and exclude minor receptor affinity differences not measurable in an ELISA assay, we
used a H+L chain transgene (VH147+Vκ14-111) on a Rag−/−
background (mk147 Rag−/−). This L chain was derived from
the original KRN5-147 hybridoma. As expected, the B cells
in mk147 Rag−/− mice strongly bound GPI (Fig. 4 A).
Importantly, both CD21/35highCD23low MZ and CD21/
35intCD23int follicular B cell subsets were present in mk147
tg mice (Fig. 4 A). CD21/35highCD23low MZ B cells were
increased in frequency in mk147 Rag−/− mice compared
with tg neg mice (24.4 ± 1.9% vs. 5.7 ± 1.3%; P = 0.004;
n = 6); however, there was not the dramatic skewing

Figure 3. Spleen and LN B cells from VH147 tg mice use similar
endogenous L chains. (A) L chain cDNA was amplified and cloned from
sorted VH147 tg spleen or LN anti-GPI B cells as described in Materials
and methods. L chain assignment was determined by using the Ig BLAST
and IMGT/V programs. The percentage of sequences using the given
L chains is depicted from a total of n = 25 sequences each from the
spleen and LN. (B) Relative affinity ELISA of VH147 tg B cells paired with
endogenous L chains. Purified Ig from VH147 tg hybridomas was plated
on serially diluted GPI-his-biotin bound to neutravidin-coated wells. Igs
with a higher relative affinity for GPI will bind to lower concentrations of
GPI than Igs with lower relative affinities. The graph represents the mean
OD ± SEM from triplicate wells, normalized as the fraction of maximal
binding. This experiment was repeated twice using at least 2 hybridomas
for each L chain, yielding similar results.
1989

observed in VH147 tg mice (59.5 ± 8.3%). This indicated
that, in addition to Vκ14-111, other L chains must have also
contributed to the GPI-binding MZ repertoire in VH147 tg
mice. The CD21/35highCD23low MZ B cells in mk147
Rag−/− mice expressed a slightly higher level of CD23 and
lower level of CD1d than MZ B cells in tg neg mice, the
reason for which was not clear (Fig. 4 A). However, when
analyzed by histology, these CD21/35highCD23low B cells
localized to the MZ, confirming that they were MZ B cells
and not a recently defined CD21/35highCD23+ MZ precursor

population that localized instead to the splenic follicle
(unpublished data) (27, 29).
The monoclonal B cell repertoire in mk147 Rag−/− mice
allowed us to clearly test whether MZ and follicular anti-GPI
B cells with identical B cell receptors still exhibited differences in autoantigen exposure (Fig. 4, B–D). Similar to the
findings in VH147 tg mice, mk147 Rag−/− B cells from all
organs tested had bound to GPI with the highest percentage
of GPI-bound cells again found in the splenic MZ (40.9 ±
6.2%; Fig. 4 C). Additionally, the MZ B cells demonstrated

Figure 4. Monoclonal anti-GPI tg mice have an expanded MZ
population with increased in vivo autoantigen exposure. (A) Spleens
from tg neg or mk147 Rag−/− mice were stained for GPI binders (left), MZ
(CD21/35highCD23low) or follicular (CD21/35int/CD23low) populations gated
on B220+ cells, or CD1d levels on CD21/35high (open histograms) overlaid
CD21/35int (shaded histograms) B cells. The percentages of follicular and
MZ cells are given for the indicated regions. (B) Cells from mk147 Rag−/−
mice (open histograms) or HELμMT (shaded histograms) were stained for

endogenously bound GPI as described in Fig. 2. The percentage and mean
fluorescence intensity are given for the indicated regions. The mean
percentage(C) and mean fluorescence intensity (D) of GPI-binding B cells
± SEM are represented as histograms. There is a significantly higher percentage of B cells bound to GPI (P < 0.03) as well as intensity of GPI
staining (P < 0.05) in the MZ compared with the other organs. BL, peripheral blood; FO, follicular. n = 5 mice of each genotype. MFI, mean
fluorescence intensity.
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the highest intensity of staining per cell (Fig. 4, B and D).
Therefore, the B cells in the MZ, as a population, have
engaged more GPI than their counterparts in other compartments. These data directly demonstrate that MZ B cells had
greater access than follicular B cells to circulating autoantigens, as had been suggested in previous studies (20, 21). Thus,
the exclusive activation of MZ anti-GPI B cells was because
a higher level of GPI autoantigen was available to them in
the MZ.
Self-Ag encounter does not render anti-GPI B cells tolerant
Autoreactive B cells that have encountered their self-Ag are
often rendered tolerant, such that they are refractory to subsequent stimulation in vivo or in vitro (30). To determine
whether the anti-GPI B cells were tolerant, spleen and LN
cells were tested for their ability to proliferate and secrete Ig
to in vitro stimuli. Anti-GPI B cells from both the VH147 tg
spleen and LN proliferated robustly to LPS, anti-CD40 +
IL-4, and cognate T cell help (KRN T cells) (Fig. 5 A). On
day 3, anti-GPI Ig was detectable in the supernatants from
VH147 tg spleen, but not LN, cells cultured with LPS, antiCD40 + IL-4, or KRN T cells (Fig. 5 B). By day 7, both
VH147 tg spleen and LN cells had secreted anti-GPI Ig in
response to LPS and KRN T cells (Fig. 5 C). The early antibody response by VH147 tg spleen cells together with their
Ig secretion in response to anti-CD40 + IL-4 alone was consistent with their MZ phenotype (22). None of the superna-

tants bound to plates coated with an irrelevant Ag, nor was
anti-GPI Ig detected in the supernatants from tg neg B cells,
confirming the specificity of the assay (Fig. 5, B and C; and
not depicted). The tg neg spleen and LN B cells did exhibit a
lower but detectable level of proliferation in response to
KRN T cell help (Fig. 5 A). This low level of proliferation
was most likely caused by a bystander response to factors such
as CD40L and IL-4. In summary, despite their encounter
with self-Ag, neither anti-GPI B cells in the spleen nor LN
were rendered unresponsive to in vitro stimulation.
B cells that have not been tolerized should have a normal
turnover rate in vivo (31). To estimate the turnover rate of
anti-GPI B cells, VH147 tg or tg neg mice were continuously labeled with BrdU for 15 d and analyzed by flow cytometry for the amount of incorporated BrdU in their spleens
and LNs (Fig. 5 D). No difference in the percentage of
BrdU+ cells was detected between the VH147 tg anti-GPI
B cells and tg neg B cells in either the spleen or the LN, nor
was there a difference when the cells were divided into
CD21/35high MZ versus CD21/35low follicular populations
(Fig. 5 D and not depicted). Previous experiments have demonstrated that some autoreactive B cells have an accelerated
turnover rate only when in the presence of nonautoreactive
B cells (32). Although VH147 tg mice contained populations
of GPI-binding and non–GPI-binding B cells, to ensure that
their normal turnover rate was not caused by the lack of
competition from non-tg B cells we measured the turnover

Figure 5. Anti-GPI B cells are not tolerant but proliferate and
secrete Ig to in vitro stimuli and have a slow turnover rate in vivo.
(A–C) Purified B cells from tg neg spleen, tg neg LN, VH147 spleen, or
VH147 LN were cultured in vitro in media alone, 25 μg/ml LPS, 10 μg/ml
anti-CD40 + 100 U/ml IL-4, or with purified KRN T cells. (A) Proliferation
was measured on day 3 as a dilution of CFSE intensity, gating on
B220+GPI+ VH147 tg or B220+ tg neg cells by flow cytometry. Data is
represented as the percentage of cells that divided ± SD (n = 3).
A greater percentage of anti-GPI B cells proliferated to KRN T cells in the
spleen (P = 0.0001) and LN (P = 0.0121) compared with tg neg B cells.
Anti-GPI Ig secretion in the culture supernatants was measured on days 3
(B) and 7 (C) by ELISA. Data is presented from a representative experiment

of triplicate wells ± SD from a minimum of 3 experiments per culture
condition. VH147 tg spleen cells produce a greater amount of anti-GPI Ig
than tg neg spleen cells to LPS, anti–CD40+IL-4, and KRN T cells on days
3 and 7 (P = 0.0001). VH147 tg LN cells produce more anti-GPI Ig than
tg neg LN cells to LPS and KRN T cells on day 7 (P = 0.0001). (D) In vivo
turnover rate. Mice were continuously labeled with BrdU for 15 d and
followed for BrdU incorporation on days 6, 10, and 15 by flow cytometry.
Histograms represent the mean percentage of incorporated BrdU ± SD
for VH147 GPI+ B cells or tg neg B cells. Four VH147 tg and three tg
neg mice were analyzed at each time point. BM chimeras are shown
for day 10 of BrdU labeling. n = 4 mixed chimeric, and n = 3 100%
chimeric mice.
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rate of anti-GPI B cells in mixed BM chimeras (Fig. 5 D).
The percentage of BrdU-labeled anti-GPI B cells was the
same whether they were in the presence of tg neg B cells
(mixed) or only VH147 B cells (100% VH147). Therefore,
the anti-GPI B cells in VH147 tg mice had a normal in vivo
turnover rate. This indicates that, although only the MZ
B cells in the spleen had up-regulated activation markers in
vivo, none of the anti-GPI B cell populations had been rendered tolerant and all remained long-lived functionally competent populations of autoreactive B cells.
Anti-GPI B cells in the MZ spontaneously secrete Ig
VH147 tg mice contain populations of anti-GPI B cells that
are fully capable of producing Ig upon in vitro stimulation.
To determine if these B cells were actively secreting antibody
in vivo, we measured anti-GPI Ig in the serum by ELISA and
anti-GPI antibody-secreting cells (ASCs) directly ex vivo by
ELISPOT (Fig. 6). All VH147 tg mice expressed low but detectable titers of anti-GPI Ig in the serum, whereas serum
anti-GPI Ig was undetectable in tg neg littermate control
mice (Fig. 6 A). This is consistent with GPI engagement on
anti-GPI B cells not only up-regulating activation markers,
but also resulting in the production of autoantibody. To
quantitate which cells were secreting the autoantibody, ASCs
were measured directly ex vivo in an ELISPOT assay. AntiGPI ASCs were detected from the spleen, but not the LN
of VH147 mice (Fig. 6 B). The fact that only the MZ GPI
binders up-regulated activation markers in response to their
exposure to GPI in vivo suggested that they might be the
population responsible for this autoantibody production. To
directly test this, the ELISPOT assay was repeated using
VH147 tg spleen samples that contained either purified follicular B cells or an enriched population of MZ B cells (Fig.
6 C). ASCs were present within the enriched MZ samples.
However, ASCs were not found in the purified follicle samples that had been depleted of MZ B cells. Therefore, only
the MZ anti-GPI B cells had differentiated into ASCs in
vivo. Collectively with Fig. 2, these data show that anti-GPI
B cells in the MZ had encountered more GPI than their
counterparts in the follicle or LN and in response became
activated to secrete autoantibody.
Anti-GPI B cells in the LN require T cell help to be recruited
into the autoimmune response
In addition to the GPI-specific B cells in the MZ, the recirculating follicular anti-GPI B cells are also a potentially dangerous population of nontolerized autoreactive B cells with
full functional capacity. However, unlike the anti-GPI B cells
in the MZ, follicular and LN anti-GPI B cells were not activated nor did they secrete autoantibody in nonautoimmune
mice. This leaves open the question of whether these ignorant anti-GPI B cells can play a role in the autoimmune response in arthritic mice. To address whether recirculating
follicular anti-GPI B cells could be recruited into the autoimmune response by autoreactive T cells in vivo, VH147 tg
mice were given cognate T cell help by breeding them to
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Figure 6. VH147 tg anti-GPI B cells in the splenic MZ but not
follicle or LN spontaneously secrete Ig. (A) Serum anti-GPI Ig titers
from VH147 tg or tg neg mice were measured by ELISA. Each symbol
represents an individual mouse for a total of 19 VH147 and 16 tg neg
mice. The mean serum titer is represented by a bar. VH147 tg serum has
higher titers of anti-GPI Ig (P = 0.0001). (B) Spontaneous ASCs from the
spleen or LN were measured by ELISPOT. Each symbol represents an individual mouse for a total of n = 8 VH147 and n = 7 tg neg mice. The
mean number of ASCs for each is represented by a histogram. More antiGPI ASCs are detected in the VH147 spleen compared with VH147 LN
(P = 0.0002) or tg neg spleen or LN (P = 0.0003). (C) Spontaneous ASCs
from purified follicular or MZ VH147 tg splenic B cells were measured by
ELISPOT. Each symbol represents a pool of three mice with the mean
number of ASCs represented by a histogram. Anti-GPI ASCs are found
only in the MZ population (P = 0.0286). This experiment was repeated
three times for a total of four pools of mice.

KRN (anti-GPI TCR) tg mice on a (C57BL/6xNOD)
F1 background. All of the VH147/KRN tg mice developed
arthritis between 4–5 wk of age (Fig. 7 A). This was slightly
delayed compared with their KRN littermates without the
VH147 tg, most likely because of the IgM transgene skewing
the B cells away from the pathogenic anti-GPI IgG1 Ig. Consistent with this, VH147 tg mice also developed slightly lower
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serum titers of anti-GPI IgG1 (non-tg Ig) and total anti-GPI
Ig titers (Fig. 7 B and not depicted). Importantly, however,
VH147/KRN tg mice did develop arthritis with the same
severity as their VH147 negative littermates (Fig. 7 A), and
their serum anti-GPI Ig titers increased as disease progressed,
unlike the constant low level of anti-GPI Ig detected in nonautoimmune VH147 tg mice (Fig. 7 B). Therefore, these
mice allowed us to determine whether the anti-GPI B cells in
the recirculating follicular pool could be engaged in the autoimmune response.

To measure the anti-GPI B cell response in VH147/
KRN tg mice, the number of anti-GPI ASCs was assayed in
the spleens and LNs of prearthritic and arthritic mice (Fig. 7,
C and D). To distinguish between tg and non-tg Ig, both
IgM (tg only; Fig. 7 C) and total Ig (tg + endogenous Ig; Fig.
7 D) anti-GPI ASCs were counted. Pre-arthritic VH147/
KRN tg, like VH147 tg alone, mice contained IgM anti-GPI
ASCs in the spleen (35.9 ± 9.6 ASCs/105 spleen cells), but
not LN. Importantly, in arthritic VH147/KRN tg mice, IgM
anti-GPI ASCs were now present in large numbers in the

Figure 7. Anti-GPI LN cells are recruited into the autoimmune
response by in vivo T cell help. VH147 tg mice were bred to KRN tg
mice on a (C57BL/6.K x NOD)F1 background and followed from 3–10 wk
for the development of arthritis (A) and serum anti-GPI autoantibodies
(B). VH147/KRN, KRN, and control mice (VH147 and tg neg) are shown.
Symbols represent the mean ± SEM. n = a minimum of 8 mice per

genotype. (C) Spontaneous anti-GPI IgM (top) or total Ig (bottom) ASCs
from the spleen or LN were measured by ELISPOT. Prearthritic mice were
3 wk old, arthritic mice were 5–8 wk old, and control nonarthritic mice
were 6–8 wk old. Each symbol represents an individual mouse for a minimum of 5 prearthritic, 10 arthritic, and 5 nonarthritic control mice of
each genotype.
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LNs (242.1 ± 64 ASCs/105 LN cells). In contrast, IgM antiGPI ASCs were low to undetectable in prearthritic or arthritic KRN mice without the VH147 transgene, confirming
that the ASCs were VH147 tg in origin. When total anti-GPI
ASCs were compared between VH147/KRN and KRN tg
alone arthritic mice, a similar large number of ASCs was
found in the LN (VH147/KRN, 465.5 ± 116.2 ASCs/105
LN cells; KRN, 512.3 ± 106 ASCs/105 LN cells). This indicated that the VH147 tg anti-GPI ASCs were representative
of the anti-GPI ASCs found in non-Ig tg arthritic mice with
respect to both timing and location (Fig. 7 D) (33). Collectively, these data demonstrate that although anti-GPI B cells
in the recirculating B cell pool of VH147 tg mice were ignorant in nonautoimmune mice, they could be recruited into
an autoimmune response by T cell help in vivo.
DISCUSSION
In this study we described a new Ig tg model, VH147, and
used it to follow the fate of an oligoclonal population of low
affinity GPI-reactive B cells. These mice revealed two functionally distinct populations of anti-GPI B cells, one enriched
in the splenic MZ and the other in the recirculating follicular
pool. We demonstrated that, despite evidence of Ag encounter beginning in the BM and continued Ag binding in the
periphery, none of the GPI-reactive B cells were rendered
tolerant in nonautoimmune mice. However, only the antiGPI B cells in the MZ were activated and spontaneously secreted autoantibody in vivo. We also showed, using a H+L
tg mouse, that the selective activation of these MZ GPIbinders was caused by increased exposure to GPI autoantigen
in the MZ and not to differences in the relative affinity of
these B cells compared with those in the follicular pool. Finally, we demonstrated that the recirculating follicular antiGPI B cells remained functionally competent and could be
activated to secrete autoantibodies when given GPI-specific
T cell help in vitro and in vivo. This study shows that low affinity anti-GPI B cells can contribute to autoantibody production in both T cell–dependent and –independent ways
and suggests that they have the potential to induce an arthritogenic autoimmune response.
Our low affinity VH147 tg model allowed us to make the
important and surprising finding that B cells were not tolerant to the ubiquitously expressed and circulating autoantigen
GPI, despite evidence for binding to it in vivo. Stable and
functional GPI exists as a homodimer (34) and therefore
should be of sufficient valency to cross-link the BCR, as opposed to the monomeric Ags previously described to induce
tolerance in B cells (35). However, the nontolerant B cells
comprised two distinct populations. The GPI-specific B cells
in the MZ were activated because of their higher exposure to
the circulating autoantigen. In contrast, those in the follicle/
LN were ignorant but could become activated when provided with T cell help. Ignorant self-reactive B cells with low
affinity Ig receptor transgenes have been described previously
(17, 19). In these models, it was proposed that the low affinity interaction was not strong enough to either activate or
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tolerize the B cells. This appears to be the case for the low
level of Ag encountered by anti-GPI B cells in the recirculating follicular B cell pool. Strikingly, however, low affinity
VH147 tg anti-GPI B cells in the MZ did show evidence of
a productive Ag encounter. They had GPI bound to their Ig
receptor and, in response, had both up-regulated activation
markers and differentiated into ASCs. The concept of differential ignorance/tolerance to autoantigens has also been described before in the case of peritoneal B-1 B cells compared
with their splenic B-2 counterparts and has been attributed to
either increased susceptibility of B-2 B cells to tolerance
induction (36) or lack of Ag exposure in the peritoneum
(37, 38). What is unique about our system is that we demonstrated both ignorant and activated anti-GPI B cell populations, with compartmentalization into the MZ allowing these
particular GPI-reactive B cells more access to their autoantigen. Because MZ B cells can be activated by lower levels of
stimulation (22), the anti-GPI B cells in the MZ had a dual
advantage over their counterparts in the follicle. They required less stimulation to become activated and, because of
their anatomical location, encountered enough Ag to exceed
that threshold.
Our findings differ considerably from a recently published
high affinity anti-GPI Ig knock-in model in which the antiGPI B cells were tolerized, either by developmental arrest or
through receptor editing (39). These features of tolerance
have been described previously and are well-characterized
fates for high affinity autoreactive B cells (1–5, 9–13). A striking difference between the two models was that we found
low affinity VH147 tg anti-GPI B cells were enriched in the
splenic MZ, whereas they found no MZ enrichment of their
anti-GPI B cells. This is consistent with the concept that
there is an affinity threshold required for MZ B cell development (21, 22, 24, 25). Finally, we demonstrated that our low
affinity GPI-reactive B cells remained functionally competent to proliferate and secrete autoantibody in response to in
vitro and in vivo stimuli, whereas their high affinity anti-GPI
B cells were poorly responsive in vitro (39). Together, this
reinforces the importance of studying B cells with low affinity for self Ags.
The precise role of either the activated MZ or ignorant
follicular/LN anti-GPI B cells in the pathogenic autoantibody response has not been established. Arthritis in K/BxN
mice is dependent on high affinity IgG1 anti-GPI Igs (7). Not
surprisingly then, the low affinity IgM autoantibodies secreted
by the MZ B cells described here did not by themselves induce disease. In VH147 tg mice, the activated MZ and ignorant follicular/LN autoreactive B cells exist concurrently,
raising the possibility that they could act coordinately to initiate the autoimmune response. Interestingly, MZ B cells have
been shown to initiate immune responses by transporting
IgM Ag-immune complexes into the follicle where they deposit them on follicular dendritic cells via receptors such
as Cr1 and Cr2 (40). These experiments suggest that MZ B
cells are in position to be the first responders to foreign Ags
circulating in the blood and may be the catalyst for driving
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follicular B cell responses to these Ags. Likewise, MZ B cells
would also be in close contact with autoantigens circulating
in the blood and, if activated, could trigger autoimmune
responses. Indeed, we demonstrated that more anti-GPI
B cells in the MZ than in the recirculating follicular compartment have bound GPI. This raises the interesting possibility
that these low affinity anti-GPI MZ B cells could augment
the activation of pathogenic follicular B cells through the formation and transport of IgM/GPI immune complexes. Alternatively, it is also possible that the low affinity anti-GPI IgM
could play an inhibitory role, acting instead to clear GPI from
the circulation via a complement-mediated process (41, 42).
Future experiments will be required to distinguish between
these possibilities.
In K/BxN mice, the autoimmune response involves GPIreactive KRN T cells as well as anti-GPI B cells (7). We
demonstrated that the LN/follicular anti-GPI B cells were
able to be stimulated to produce anti-GPI autoantibodies by
KRN T cells both in vitro and in vivo. The potential for
T cell help to rescue/activate autoreactive B cells has been
controversial. Activation of autoreactive B cells has been
demonstrated in autoimmune mice; however, because of the
lack of reagents to identify Ag-specific T cells, the role of
cognate T cell help could only be inferred (43–45). Other
studies used surrogate forms of cognate T cell help and demonstrated that anergy in autoreactive B cells was able to be
prevented or even reversed in some systems, whereas in others anergic B cells were not able to be rescued (46–49). These
outcomes were attributed to differences in the valency or
avidity of the self-Ag studied and/or the timing and quality
of T cell help. Our model is unique in that we are able to
provide our self-reactive B cells with help from T cells recognizing the same well-defined self-Ag, and all of this could
be done during the development of autoimmunity. Therefore, we were able to show directly that GPI-specific B cells
were stimulated to produce autoantibody by GPI-specific
T cell help during the development of arthritis in vivo. Although the anti-GPI B cells in our study had a low affinity for
self-Ag and therefore did not directly induce disease, we contend that these nontolerant B cells are representative of autoreactive B cells that escape tolerance induction and, under
the appropriate conditions, could initiate autoimmune responses. There is precedence in another autoantigen response
suggesting that high affinity autoreactive B cells can be derived from low affinity precursors (50). We propose then,
that low affinity anti-GPI B cells can contribute to the autoantibody response by two distinct mechanisms depending on
their compartmentalization. MZ anti-GPI B cells are spontaneously activated, whereas those in the follicle/LN require
T cell help.
MATERIALS AND METHODS
Mice. KRN TCR tg C57BL/6 and K/BxN mice have been described previously (6). KRN and Rag-1−/− mice were crossed onto an H-2k background (B6.K; The Jackson Laboratory). HELμMT were obtained from
Herbert W. Virgin (Washington University, St. Louis, MO) (51). Cr2deficient mice, originally obtained from Hector Molina (Washington
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University, St. Louis, MO) (28), were bred to VH147 tg mice and maintained in our colony. To obtain arthritic mice, VH147 tg B6.K mice were
crossed to KRN B6.K mice and then subsequently crossed to NOD to generate VH147/KRN BxN mice. Tg mice were generated in the Washington
University Department of Pathology transgenic core facility. Age-matched
tg neg B6.K or tg neg (B6.K × NOD) F1 mice were used as controls in all
experiments. All mice were bred and housed under specific pathogen-free
conditions in the animal facility at the Washington University Medical Center. Experiments were performed in accordance with the National Institutes
of Health and the Association for Assessment and Accreditation of Laboratory Animal Care guidelines.
Hybridoma generation. Unmanipulated spleen and LN cells from individual arthritic K/BxN mice (6 wk old) or pooled VH147 B6.K mice
(5 mice per fusion aged 6–8 wk each) were fused to the Ig− myeloma, SP2/0,
as described previously (52). Cells were immediately plated at limiting dilution, and wells bearing single colonies were expanded for analysis. Hybridomas were screened by ELISA for binding to GPI-his protein and for
Ig isotype. The KRN5-147 hybridoma bound specifically to GPI and not
to the other cytoplasmic proteins, enolase, GAPDH, or hexokinase
(unpublished data).
Flow cytometry. BM, spleen, peritoneal cavity, LN, and peripheral blood
cells (106 each) were stained with commercially available antibodies (see
Supplemental materials and methods, available at http://www.jem.org/cgi/
content/full/jem.20060701/DC1). mGPI-his protein was conjugated to biotin using N-hydroxysuccinimidobiotin (Sigma-Aldrich) in our laboratory.
For GPI receptor occupancy studies, cells were stained with anti-B220–APC,
anti-CD21/35–PE (BD Biosciences), and an FITC-conjugated pool of antiGPI mAbs generated in our laboratory (KRN5-19, -28, -46, and -50.1) that
bind to epitopes distinct from the KRN5-147 Ig, either with or without
prior incubation with GPI-his.
All samples were analyzed on a flow cytometer (FACSCalibur; BD Biosciences) with CellQuest software (BD Biosciences). In some experiments
the vital dye 7-amino-actinomysin D (Sigma-Aldrich) was added to exclude
dead cells. Gating on live lymphocytes was based on forward and side scatter,
and 50,000–100,000 events were collected for each sample.
BrdU labeling. Mice were labeled with 0.8 mg/ml BrdU (Sigma-Aldrich)
in their drinking water for 15 d. The BrdU water was changed daily. Cells
with an increased turnover rate as well as cells that were actively proliferating
in the spleen and LN were labeled. To distinguish between proliferation and
turnover, mice were pulsed with 1 mg/ml BrdU i.p. for 2 h to assess the in
vivo proliferation status of the B cells. Only a small percentage of the GPIbinding B cells in the spleen and LN incorporated BrdU during the 2-h
pulse (0.8% VH147 vs. 1.2% tg neg; n = 3), indicating that they are not actively proliferating in vivo. Therefore, any BrdU+ cells detected during the
15-d labeling were caused by replacement from labeled BM precursors.
BrdU staining was performed as previously described (12). In brief,
spleen and BM cells from mice were isolated and surface stained to identify
GPI-binding MZ or follicular B cells as described in Flow cytometry. The
cells were then fixed and permeabilized with 1% paraformaldehyde containing 0.1% Tween 20. The DNA was denatured using 10 μM HCl and
100 U/ml DNaseI. The incorporated BrdU was then detected using an antiBrdU–FITC antibody (PRB-1) from eBioscience.
Anti-GPI ELISA. Serum samples, plated at an initial dilution of 1:50 and
diluted serially 1:2 (nonarthritic mice) or 1:10 (arthritic mice), or undiluted
culture supernatants were plated in plates (Immulon II; Fisher Scientific) coated
with 5 μg/ml GPI-his. Donkey anti–mouse total Ig-horseradish peroxidase
(HRP; Jackson ImmunoResearch Laboratories) and goat anti–mouse IgM,
IgG1, IgG2a, IgG2b, and IgG3-HRP (Southern Biotechnology Associates, Inc.)
were used as secondary antibodies. Serum antibody was detected using a
substrate (ABTS; Roche Applied Science). The serum titer was defined as the
reciprocal of the last dilution which gave an OD >3× background.
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Anti-GPI affinity ELISA. Igs were tested for their relative affinity for GPI
by titration of binding in an ELISA assay as described previously (53). Hybridoma IgM from tissue culture supernatant were purified using ImmunoPure immobilized mannan-binding protein according to manufacturer’s
instructions, except that the supernatant was concentrated before dialysis into
binding buffer (Pierce Chemical Co.). 200 μg/ml purified hybridoma Igs
were then tested in triplicate for binding to GPI-his, plated at an initial dilution of 10 μg/ml, and diluted serially 1:2 on Immulon II plates coated with
10 μg/ml neutravidin. Goat anti–mouse IgM-HRP was used as a secondary
antibody and detection was done as described for the anti-GPI ELISA.
Anti-GPI ELISPOT assay. Spleen or LN cells were plated at 4 × 105
cells/well and diluted serially 1:4 in mixed cellulose ester membrane plates
(Multiscreen HA; Millipore) coated with 5 μg/ml GPI-his. The cells were
incubated on the Ag-coated plates at 37°C for 4 h. The Ig secreted by the
plated cells was detected by alkaline phosphatase–conjugated goat anti–mouse
total Ig or IgM secondary antibodies (Southern Biotechnology Associates)
and visualized using NBT/BCIP substrate (Sigma-Aldrich).
Purification of MZ versus follicular B cells. Pooled spleens from
VH147 tg mice (n = 3 per sample) were enriched for follicular or MZ B cells
using a separation system (MACS; Miltenyi Biotech) in a two-step process.
First, the cells were stained with anti-CD21–FITC and anti-CD23–PE, followed by anti-PE paramagnetic beads (Miltenyi Biotech). The CD23+
(PE+) follicular B cells were collected as the positive fraction. The CD23−
fraction was then bound to anti-FITC paramagnetic beads (Miltenyi Biotech). The CD23−CD21+ MZ B cells were then collected as the positive
fraction. Cell purity for follicular B cells was >90% with less than 1% contaminating MZ B cells. MZ B cells were enriched to 65% with 1–2% contaminating follicular B cells.
In vitro stimulation. B cells from tg neg or VH147 tg B6.K or (B6.K ×
NOD)F1 spleen and LN and KRN T cells were purified using the MACS
separation system with paramagnetic anti-CD43 or anti-CD4 beads, respectively. Cell purity was >95%. Cells were labeled with 5 μM CFSE (Invitrogen). 106 B cells were cultured in a 1-ml total volume in either media alone
(Iscoves-DME, 10% FCS, 5 × 10−5 M 2-mercaptoethanol), 50 μg/ml LPS
(Escherichia coli strain 0111:B4; Sigma-Aldrich), 10 μg/ml anti-CD40
(clone 1C10; R&D Systems) + 100 U/ml IL-4 (grown as supernatant from
IL-4–transfected P815 cells), or 0.5 × 106 KRN T cells. To determine if the
VH147 tg anti-GPI B cells could respond to cognate T cell help, VH147 tg
(B6.K × NOD) F1 mice were generated to obtain B cells that express the
I-Ag7 MHC class II molecule for presentation of GPI peptide to KRN tg
T cells (6). VH147 tg anti-GPI B cells have an identical surface phenotype in
B6.K and (B6.K × NOD) F1 mice and therefore were used interchangeably
(unpublished data). Proliferation was measured on day 3 by flow cytometry
as a decrease in CFSE intensity relative to unstimulated cells. Anti-GPI Ig
secretion in tissue culture supernatants was determined on days 3 and 7 by
anti-GPI ELISA.
Mixed BM chimeras. Lethally irradiated (1,000 Rad) B6.K mice were reconstituted with 20 × 106 total BM cells containing either 95% VH147 +
5% tg neg, 100% VH147 tg, or 100% tg neg cells. The resulting mixed chimeras contained 20% VH147 tg B cells. Chimeras were allowed to reconstitute for 6 wk and were then labeled with BrdU for 10 d before analysis.
Cloning and sequencing of VH147 L chains. GPI-binding B cells from
VH147 tg spleen and LN, pooled from 15 mice each, were sorted using a
high speed flow cytometer (MoFlo; DakoCytomation). RNA from the
sorted cell populations was isolated using the RNeasy kit (QIAGEN) and
stored at −70°C before analysis. cDNAs were generated using a Cκ primer.
L chain sequences were then amplified using the Cκ 3′ primer with the degenerate 5′ primer, L3′ (52). The resulting PCR products were then cloned
using a cloning kit for sequencing (TOPO TA; Invitrogen) and sequenced
using a terminator mix (Big Dye; Applied Biosystems) and the M3 reverse
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primer from the vector sequence. L chain designation was determined by
comparison to published sequences in the GenBank database using the Ig
BLAST (available at http://www.ncbi.nlm.nih.gov/projects/igblast) and
IMGT/V-Quest (http://imgt.cines.fr) programs. Alignment of L chain sequences using the same Vκ gene showed several nucleotide differences
within the V region (most yielding silent mutations) and usage of different
Jκ genes, demonstrating that they were derived from independent clones
(unpublished data).
Arthritis incidence. The two rear ankles were measured starting at the age
of 3 wk. Measurement of ankle thickness was made above the footpad,
axially across the ankle joint using a metric pocket thickness gauge (Fowler;
Ralmikes Tool-A-Rama). Ankle thickness was rounded off to the nearest
0.05 mm.
Statistical analysis. Statistical significance was determined using an
unpaired Student’s t test or the Mann-Whitney nonparametric test.
Online supplemental material. Fig. S1 shows the allelic exclusion of
endogenous Ig by the VH147 transgene. Fig. S2 shows immunofluorescence
staining demonstrating expanded MZs in VH147 tg mice. Fig. S3 shows
phenotypic marker staining on control non-GPI binding B cells in VH147
tg mice. Supplemental materials and methods include the cloning of the
H and L chain genes for generating the tg Ig, generation of the recombinant
GPI-his protein, antibodies used for flow cytometry, and the immunofluorescence staining protocol. Online supplemental material is available
at http://www.jem.org/cgi/content/full/jem.20060701/DC1.
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